INOVIO to Present at Upcoming Scientific Conferences

Rhea-AI Summary

INOVIO (NASDAQ:INO) has announced its participation in several upcoming scientific conferences to present data on its lead candidate INO-3107 and DNA medicine technologies. At the National HPV Conference in Indianapolis on April 15, the company will present results showing a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.

The company will also participate in the World Vaccine Congress in Washington, DC (April 21-23), where they will discuss their DNA-encoded monoclonal antibody (DMAb™) technology and DNA immunotherapeutics for cancer and viral diseases. Additionally, INOVIO will present at the Festival of Biologics in San Diego on April 23, focusing on INO-3107 for Recurrent Respiratory Papillomatosis. Abstracts will be available on INOVIO's website after the presentations.

PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.

National HPV Conference (Indianapolis, IN)
April 15:

• Oral presentation: DNA Immunotherapy (INO-3107) Results in a 72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11
• Panel: Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences – Moderated by Kim McClellan, RRP Foundation President

World Vaccine Congress (Washington, DC)
April 21:

• Oral presentation: A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb™) as Next Gen DNA Medicine

April 23:

• Oral presentation: DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases

Festival of Biologics (San Diego, CA)
April 23:

• Oral presentation: Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302424147.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What is the success rate of INOVIO's INO-3107 treatment for RRP?

INO-3107 achieved a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.

Which scientific conferences will INOVIO (INO) present at in April 2025?

INOVIO will present at the National HPV Conference (April 15), World Vaccine Congress (April 21-23), and Festival of Biologics (April 23).

What new technology will INOVIO showcase at the World Vaccine Congress 2025?

INOVIO will showcase their DNA-encoded monoclonal antibody (DMAb™) technology as a next-generation DNA medicine.

What diseases does INOVIO's DNA medicine portfolio target?

INOVIO's DNA medicines target HPV-related diseases, cancer, and infectious diseases.

When will INOVIO's presentation abstracts be available to the public?

The abstracts will be shared on INOVIO's website following the presentations at the respective conferences.